TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20664838

Group type: EXPERIMENTAL
Intervention: 0.3 mg/mL recombinant human platelet‐derived growth factor (rhPDGF‐BB) with beta‐tricalcium phosphate (b‐TCP)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.3 mg/mL recombinant human platelet‐derived growth factor (rhPDGF‐BB) with collagen containing anorganic deproteinized bovine bone (xenograft)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.3 mg/mL recombinant human platelet‐derived growth factor (rhPDGF‐BB) with either b‐TCP or xenograft
Number of subjects: 12
Study: 18248280

Group type: EXPERIMENTAL
Intervention: 1-level lumbar arthroplasty (Charité Artificial Disc)
Number of subjects: 276
Study: 16877370

Group type: EXPERIMENTAL
Intervention: Letrozole and FSH
Number of subjects: 432

Group type: COMPARATOR
Intervention: FSH only
Number of subjects: 432
Study: 14499772

Group type: EXPERIMENTAL
Intervention: Lansoprazole, clarithromycin, and amoxicillin (LCA)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 10655965

Group type: EXPERIMENTAL
Intervention: EPA/DHA (1.05 g EPA plus 0.55 g DHA)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (6.8 g/d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oleic acid (diet during run-in period)
Number of subjects: 50
Study: 9101884

Group type: EXPERIMENTAL
Intervention: Extraperitoneal approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transperitoneal approach
Number of subjects: 0
Study: 2065506

Group type: EXPERIMENTAL
Intervention: Intra-articular steroid injection (1 or 2 knees)
Number of subjects: 20
Study: 6132218

Group type: EXPERIMENTAL
Intervention: Low-residue liquid supplement
Number of subjects: 28

Group type: COMPARATOR
Intervention: Ordinary diet
Number of subjects: 28
Study: 4065108

Group type: EXPERIMENTAL
Intervention: Aerobic/Circuit Weight Training (A/CWT) for 10 weeks at 60% of 1RM
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Aerobic/Circuit Weight Training at 70% of 1RM (A/CWT-70)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Aerobic/Circuit Weight Training at 40% of 1RM (A/CWT-40)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Standard Navy Aerobic/Calisthenic Training (A/CAL)
Number of subjects: 137
Study: 30572864

Group type: COMPARATOR
Intervention: Unhealthy food sponsorship
Number of subjects: 1132

Group type: COMPARATOR
Intervention: Healthier food sponsorship
Number of subjects: 1132

Group type: COMPARATOR
Intervention: Obesity prevention campaign sponsorship
Number of subjects: 1132
Study: 26490126

Group type: EXPERIMENTAL
Intervention: Monitored group (dETCO2 monitoring)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Masked group (no dETCO2 monitoring)
Number of subjects: 55
Study: 24164904

Group type: EXPERIMENTAL
Intervention: Rabeprazole (5 or 10 mg for low-weight cohort; 10 or 20 mg for high-weight cohort)
Number of subjects: 90
Study: 22389273

Group type: EXPERIMENTAL
Intervention: Standard diet with eicosapentaenoic acid‐enriched supplementation for 7 days before surgery and for 21 days after surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: No supplementation with oral nutrients (standard diet)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard diet with eicosapentaenoic acid‐enriched supplementation
Number of subjects: 0
Study: 20159179

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Thermal balloon ablation (TBA)
Number of subjects: 58
Study: 18398307

Group type: EXPERIMENTAL
Intervention: Purified Chick Embryo Cell Vaccine (PCECV) administered as a three-dose regimen (1.0 mL or 0.5 mL)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Purified Verocell Rabies Vaccine (PVRV) administered as a three-dose regimen (0.5 mL)
Number of subjects: 175
Study: 15718046

Group type: EXPERIMENTAL
Intervention: Stroke patients with cognitive impairment (VaD and VCI)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Stroke patients without cognitive impairment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Healthy elderly controls
Number of subjects: 48
Study: 14728348

Group type: EXPERIMENTAL
Intervention: Personalized menopause decision support aid (DSA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 10912985

Group type: EXPERIMENTAL
Intervention: 5% lidocaine‐prilocaine
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 30% lidocaine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (acid‐mantle cream)
Number of subjects: 61
Study: 9072226

Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No administration of T3
Number of subjects: 0
Study: 1984366

Group type: EXPERIMENTAL
Intervention: 20 mL of 0.5% bupivacaine with 1:200,000 epinephrine through the single catheter
Number of subjects: 20

Group type: COMPARATOR
Intervention: 10 mL of 0.5% bupivacaine with or without 1:200,000 epinephrine through each of the two catheters
Number of subjects: 20
Study: 6407054

Group type: EXPERIMENTAL
Intervention: Clobazam 20 mg (an anxiolytic 1,5‐benzodiazepine derivative)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31047670

Group type: EXPERIMENTAL
Intervention: Immune interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27852952

Group type: EXPERIMENTAL
Intervention: Bi‐level positive airway pressure (PAP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous positive airways pressure (CPAP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bi‐level PAP
Number of subjects: 60

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 60
Study: 26095194

Group type: EXPERIMENTAL
Intervention: 1.5 ml 0.25% bupivacaine (Group B)
Number of subjects: 110

Group type: COMPARATOR
Intervention: 1.5 ml saline (Group S)
Number of subjects: 110
Study: 23775574

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 40
Study: 21450662

Group type: EXPERIMENTAL
Intervention: Hospital-based training
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Home training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Home training and Hospital training
Number of subjects: 60
Study: 19660507

Group type: EXPERIMENTAL
Intervention: 25 g glucose drink
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 0
Study: 16701989

Group type: EXPERIMENTAL
Intervention: Once-daily budesonide/formoterol (80/4.5 microg, 2 inhalations in the evening)
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Twice-daily budesonide/formoterol (80/4.5 microg, 1 inhalation)
Number of subjects: 617

Group type: COMPARATOR
Intervention: Budesonide (200 microg, 1 inhalation in the evening)
Number of subjects: 617

Group type: COMPARATOR
Intervention: Budesonide/formoterol therapy
Number of subjects: 617
Study: 15243815

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (specifics not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C(6) antibody testing
Number of subjects: 0
Study: 11345361

Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated equine estrogen daily for three months
Number of subjects: 55
Study: 9786353

Group type: EXPERIMENTAL
Intervention: Chromogranin positivity (neuroendocrine cell expression)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Long-term cancer-free survival
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Correlation of chromogranin positivity with survival
Number of subjects: 48
Study: 7603732

Group type: EXPERIMENTAL
Intervention: 15 mmol of magnesium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3044484

Group type: EXPERIMENTAL
Intervention: Cephradine prophylaxis (3 peri-operative doses)
Number of subjects: 243

Group type: COMPARATOR
Intervention: No antibiotic (control)
Number of subjects: 243
Study: 31796208

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 2332

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 2332
Study: 31307948

Group type: EXPERIMENTAL
Intervention: Dolutegravir (50 mg) plus Rilpivirine (25 mg) orally once daily (early-switch group)
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Standard ART regimen (late-switch group)
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Dolutegravir plus Rilpivirine (early-switch group)
Number of subjects: 1024
Study: 28105994

Group type: EXPERIMENTAL
Intervention: O‐SES
Number of subjects: 372

Group type: COMPARATOR
Intervention: R‐ZES
Number of subjects: 372
Study: 24671714

Group type: EXPERIMENTAL
Intervention: Theobromine-containing toothpaste (Theodent-classic-F®)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Theobromine-containing toothpaste (Theodent-classic®)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Novamin®-containing toothpaste (Sensodyne®-5000-Nupro)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fluoride toothpaste (Colgate®-Regular)
Number of subjects: 80
Study: 23067311

Group type: EXPERIMENTAL
Intervention: 200 mg GSK1144814
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 20
Study: 22136026

Group type: EXPERIMENTAL
Intervention: Scalp and body acupuncture (group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Body acupuncture (group A)
Number of subjects: 20
Study: 19840020

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDChT) with autologous stem cell support (ASCS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential HD regimen with one or two conventional chemotherapy cycles followed by two or three HD cycles of CE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDChT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional-dose chemotherapy
Number of subjects: 0
Study: 16998274

Group type: EXPERIMENTAL
Intervention: Fasudil hydrochloride (30 mg by intravenous injection over 30 minutes three times a day for 14 days)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Nimodipine (1 mg/hr by continuous intravenous infusion for 14 days)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fasudil hydrochloride
Number of subjects: 72

Group type: COMPARATOR
Intervention: Nimodipine
Number of subjects: 72
Study: 14714931

Group type: EXPERIMENTAL
Intervention: Anxiety, Depression, and Mood Scale (ADAMS)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: ADAMS
Number of subjects: 129
Study: 11097664

Group type: EXPERIMENTAL
Intervention: 24-gauge epidural catheter through a 19-gauge Tuohy needle (Group EC)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 28-gauge microcatheter through a 22-gauge spinal needle (Group MC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 22-gauge spinal catheter over a 27-gauge spinal needle through an epidurally placed 18-gauge Crawford needle (Group SC)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study: 9494056

Group type: EXPERIMENTAL
Intervention: Lifestyle program including a low-fat diet and weekly moderate exercise (Experimental group, N = 27)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care (Control group, N = 29)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Experimental group (N = 27)
Number of subjects: 56
Study: 8342838

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combined groups (Clonidine and Placebo)
Number of subjects: 21
Study: 3668249

Group type: EXPERIMENTAL
Intervention: Atenolol (beta 1-selective agent) with or without diuretics and/or vasodilators
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Atenolol treatment
Number of subjects: 939
Study: 31617235

Group type: EXPERIMENTAL
Intervention: Valbenazine 80 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valbenazine 40 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valbenazine (combined doses)
Number of subjects: 0
Study: 29225012

Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided out-of-plane application
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional landmark method
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ultrasonography-guided in-plane application
Number of subjects: 60
Study: 27465375

Group type: EXPERIMENTAL
Intervention: Breakfast consumption
Number of subjects: 128

Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 128
Study: 24015934

Group type: EXPERIMENTAL
Intervention: NEURO (low-frequency repetitive transcranial magnetic stimulation plus occupational therapy)
Number of subjects: 66

Group type: COMPARATOR
Intervention: constraint-induced movement therapy
Number of subjects: 66
Study: 22446665

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training group (WBVG)
Number of subjects: 23
Study: 20449588

Group type: EXPERIMENTAL
Intervention: MRI follow-up after free tendon graft reconstruction
Number of subjects: 10
Study: 18234328

Group type: EXPERIMENTAL
Intervention: Poly‐Lactide‐co‐Glycolide (PLG) polymer (Fisiograft)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Platelet‐rich plasma (PRP)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Autologous bone (AB)
Number of subjects: 19
Study: 15826612

Group type: EXPERIMENTAL
Intervention: Bayesian networks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Characteristic features
Number of subjects: 0
Study: 12814142

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (AB) 1 mg/kg/day (weight < 75 kg = 50 mg/day; weight ≥ 75 kg = 100 mg/day)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (AB)
Number of subjects: 81
Study: 10824899

Group type: EXPERIMENTAL
Intervention: Modified Fontan procedure
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Senning operation
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 55
Study: 8684391

Group type: EXPERIMENTAL
Intervention: Rhythmic auditory stimulation (RAS) during a 3-week home-based gait-training program
Number of subjects: 15

Group type: COMPARATOR
Intervention: Self-paced training (control group)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Rhythmic auditory stimulation (RAS)
Number of subjects: 15
Study: 8435168

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 51
Study: 3316172

Group type: EXPERIMENTAL
Intervention: Fenfluramine hydrochloride
Number of subjects: 9

Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 9
Study: 29169952

Group type: EXPERIMENTAL
Intervention: VREMS (Virtual Reality Epley Maneuver System)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Instructional Handout (IH)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: VREMS
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NASA Task Load Index (TLX)
Number of subjects: 20
Study: 27236200

Group type: EXPERIMENTAL
Intervention: Environmental Health Practitioner (EHP) intervention
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Future interventions
Number of subjects: 276
Study: 26377368

Group type: EXPERIMENTAL
Intervention: Atomoxetine (n=12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (n=12)
Number of subjects: 24
Study: 23885521

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional cholecystectomy
Number of subjects: 120
Study: 22479740

Group type: EXPERIMENTAL
Intervention: Oral prednisolone 100 mg once daily for 72 hrs
Number of subjects: 65

Group type: COMPARATOR
Intervention: Intravenous hydrocortisone 100 mg i.v. 6 hourly for 72 hrs
Number of subjects: 65
Study: 23283393

Group type: EXPERIMENTAL
Intervention: Thrice BCG vaccinations (0.1 mL intradermal injection, 3 times every 4 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Single BCG vaccination (0.1 mL intradermal injection)
Number of subjects: 40
Study: 17190103

Group type: EXPERIMENTAL
Intervention: Test solution with Na/K molar ratio of 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test solution with Na/K molar ratio of 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test solution with Na/K molar ratio of 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test solution with Na/K molar ratio of 4
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 0
Study: 15046683

Group type: EXPERIMENTAL
Intervention: Flutamide
Number of subjects: 794

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 794
Study: 10753986

Group type: EXPERIMENTAL
Intervention: Carotid stenting (successful stenting)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Carotid stenting (unsuccessful stenting)
Number of subjects: 14
Study: 8575136

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) at 3-5 mg/kg/day
Number of subjects: 35

Group type: COMPARATOR
Intervention: Low-dose Methotrexate (MTX) at 2.5 mg every 12 hours for 3 consecutive doses each week up to 15 mg/week
Number of subjects: 35

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) and Methotrexate (MTX)
Number of subjects: 35
Study: 2791446

Group type: EXPERIMENTAL
Intervention: 3200 mg ibuprofen
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 362791

Group type: EXPERIMENTAL
Intervention: Myoinositol
Number of subjects: 59
Study: 31273459

Group type: COMPARATOR
Intervention: Not treated by a specialist (RA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical therapy (all three diagnoses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Depressive symptoms (axSpA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Claims data validity
Number of subjects: 0
Study: 28602530

Group type: EXPERIMENTAL
Intervention: 25-mm magnification marker
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard 21% magnification
Number of subjects: 100
Study: 26001510

Group type: EXPERIMENTAL
Intervention: High-rate therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-delay therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional ICD programming
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (arm A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (arm B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (arm C)
Number of subjects: 0
Study: 24113668

Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (EQW)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Basal insulin (b-INS)
Number of subjects: 263
Study: 21586650

Group type: EXPERIMENTAL
Intervention: CoQ10 (100 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 18755849

Group type: EXPERIMENTAL
Intervention: 6-variable Modification of Diet in Renal Disease (6-MDRD)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 4-variable MDRD (4-MDRD)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Cockcroft-Gault (CG)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Cockcroft-Gault equations corrected for body surface area (CGC)
Number of subjects: 155
Study: 16926172

Group type: EXPERIMENTAL
Intervention: new formulation (vitamins B1, B2, B6, B12, and folic acid)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: old formulation (vitamins B1, B2, B6, and B12)
Number of subjects: 325

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 325
Study: 15049015

Group type: EXPERIMENTAL
Intervention: CCG-1991
Number of subjects: 140

Group type: COMPARATOR
Intervention: Other CCG leukemia studies
Number of subjects: 140
Study: 11390122

Group type: EXPERIMENTAL
Intervention: Aerodiol 300 microg daily
Number of subjects: 361

Group type: COMPARATOR
Intervention: Transdermal 17 beta‐estradiol (50 microg/day, 2 patches per week)
Number of subjects: 361
Study: 9198496

Group type: EXPERIMENTAL
Intervention: Isometric exercise
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Isotonic exercise
Number of subjects: 22
Study: 8313635

Group type: EXPERIMENTAL
Intervention: 1% griseofulvin spray applied twice daily for 14 days
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo (vehicle) applied twice daily for 14 days
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 1% griseofulvin spray applied once daily for 4 weeks
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo (vehicle) applied once daily for 4 weeks
Number of subjects: 116
Study: 2827545

Group type: EXPERIMENTAL
Intervention: Buffered 1% lidocaine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Buffered 1% lidocaine with epinephrine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Buffered 1% mepivacaine
Number of subjects: 25
Study: 31563383

Group type: EXPERIMENTAL
Intervention: Therapeutic exercise (TE) combined with integrated neuromuscular inhibition technique (INIT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Therapeutic exercise (TE)
Number of subjects: 40
Study: 28810251

Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg q.d. for 1 month followed by 5 mg q.d. for maintenance
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg b.i.d. for 1 month followed by 45 mg b.i.d. for maintenance
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg q.d. for 1 month followed by standard dose without reduction
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All groups (Prasugrel, Ticagrelor, Clopidogrel)
Number of subjects: 100
Study: 25412795

Group type: EXPERIMENTAL
Intervention: ALV 600 mg QD + PR
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: ALV 800 mg QD + PR
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: ALV 400 mg BID + PR
Number of subjects: 459

Group type: COMPARATOR
Intervention: Placebo + PR
Number of subjects: 459

Group type: COMPARATOR
Intervention: PR alone
Number of subjects: 459
Study: 22324720

Group type: EXPERIMENTAL
Intervention: Topical 0.1% tacrolimus ointment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 26
Study: 21691613

Group type: EXPERIMENTAL
Intervention: Gold OD
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ti OD
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: IFP
Number of subjects: 41